



CIN No : L24239MH1987PLC043662

Date: 12th February 2024

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai - 400 001

Scrip Code: 539730

Dear Sir/ Madam,

Sub.: Press Release issued by Fredun Pharmaceuticals Limited

Please find enclosed press release titled "**Fredun Pharmaceuticals Secures Orders from SEA Countries, Expands Product Development in Veterinary Care, and Advances Orthopaedic Applications**" issued by Fredun Pharmaceuticals Limited.

Kindly take the same on your records and acknowledge the receipt.

Thanking you.

Yours truly,

For **Fredun Pharmaceuticals Limited**

Jinkal Soni
(Jinkal Shah)
Company Secretary and Compliance Officer

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 **Fax:** 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: business@fredungroup.com **Web:** www.fredungroup.com



FREDUN PHARMACEUTICALS LIMITED

Press Release
For Immediate Dissemination

PRESS RELEASE

Fredun Pharmaceuticals Secures Orders from SEA Countries, Expands Product Development in Veterinary Care, and Advances Orthopaedic Applications

Mumbai, India | February 9, 2024

Fredun Pharmaceuticals Limited (BSE: 539730), a leading provider of innovative healthcare solutions, is pleased to announce significant milestones in its business expansion and product development initiatives.

Breakthrough Orders from SEA Countries: Fredun Pharmaceuticals has received large orders from Southeast Asian (SEA) countries, amounting to Rs 28 crores. These orders not only demonstrate the Company's growing presence in the international markets but also hold substantial potential to scale up over the years, signifying a promising avenue for future growth and market penetration.

Innovative Ventures in Veterinary Product Development: As part of its commitment to pioneering advancements in pet and veterinary care, Fredun Pharma has initiated the development of three new molecules. These ground-breaking formulations, the first of their kind in India, are poised to revolutionize the landscape of veterinary medicine, addressing critical needs and enhancing the well-being of companion animals. This strategic endeavour underscores the Company's dedication to innovation and meeting evolving market demands in the veterinary sector.

Advancements in Bone Graft Technology: Building on the success of its bone graft products, Fredun Pharma is proud to announce widespread acceptance by medical professionals. Encouraged by this positive response, the Company is expanding its focus on bone grafts for use in orthopaedic and veterinary applications. This strategic move reflects the Company's commitment to delivering high-quality healthcare solutions that positively impact patient outcomes and advance medical practices in both human and animal healthcare domains.

Commenting on the milestone achievement, Mr. Fredun Medhora, Managing Director of Fredun Pharmaceuticals said, *"These recent achievements underscore our unwavering commitment to innovation, quality, and customer satisfaction. We are excited about the opportunities presented by our expanding international footprint, pioneering developments in veterinary care, and advancements in orthopaedic applications. We remain dedicated to driving positive change in healthcare and improving the lives of patients and animals worldwide."*



FREDUN PHARMACEUTICALS LIMITED

About Fredun Pharmaceuticals

Fredun Pharmaceuticals Limited, healthcare and pharmaceuticals company offer a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products along with animal healthcare products. With such a diverse range of products, the Company's objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.

For further details, please feel free to contact:

Investor Relations team at Fredun Pharmaceuticals Limited

Fredun Medhora

Managing Director, Fredun Pharmaceuticals Ltd

P: 022-4031 8111

E: investing@fredungroup.com

Registered Office

'Urmi Estate', 11th Floor,

Ganpatrao Kadam Marg, Lower Parel (W),

Mumbai – 400 013

Tel. No.: +91 22 4031 8111

Runjhun Jain/Sonia Keswani

Ernst & Young LLP

M: 98207 20993 / 80173 93854

E: runjhun.jain1@in.ey.com / sonia.keswani@in.ey.com

Disclaimer:

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Fredun and its subsidiaries/associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Fredun, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.